Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Decheng Capital Management III (Cayman), LLC 13F Holdings -- Portfolio & Top Positions (2023-09-30)

Decheng Capital Management III (Cayman), LLC (CIK 1747821) reported $299.6M across 26 reported positions in its SEC 13F filing for 2023-09-30. Largest positions: ALPN ($76.8M, 25.63%), ZNTL ($42.1M, 14.06%), AURA ($18.2M, 6.09%), ROIV ($17.0M, 5.69%), SLRN ($15.7M, 5.26%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1ALPNAlpine Immune Sciences, Inc.$76.8M25.63%6.7MNew
2ZNTLZentalis Pharmaceuticals Inc.$42.1M14.06%2.1MHold
3AURAAura Biosciences, Inc.$18.2M6.09%1.2MAdded
4ROIVROIVANT SCIENCES LTD$17.0M5.69%1.5MNew
5SLRNACELYRIN INC(NSM)$15.7M5.26%1.5MTrimmed
6RCUSArcus Biosciences, Inc$15.6M5.21%869,790Hold
7TXG10x Genomics, Inc.$14.8M4.95%359,554Hold
8ARGXArgenx SE$13.5M4.50%27,429Hold
9PACBPacific Biosciences of California, Inc.$12.2M4.08%1.5MHold
10ILMNIllumnia, Inc.$11.1M3.70%80,859Hold
11LNTHLANTHEUS HOLDINGS INC(NMS)$9.9M3.30%142,196New
12HZNPHorizon Therapeutics PLC$9.1M3.05%78,900Hold
13PHATPHATHOM PHARMACEUTICALS INC$8.8M2.94%850,000Hold
14IMGNIMMUNOGEN INC$6.6M2.20%415,880New
15SGENSEAGEN INC$4.9M1.63%23,014New
16BYSIBeyondSpring Inc.$4.0M1.32%5.0MNew
17HLTHQCue Health Inc.$4.0M1.32%9.0MHold
18TERNTerns Pharmaceuticals, Inc.$3.6M1.20%714,285Hold
19EQEquillium Inc.$3.3M1.10%4.4MHold
20WHWKAadi Bioscience, Inc.$2.5M0.85%526,329Hold
21ATRCAtriCure Inc.$2.0M0.68%46,259New
22SCYXScynexis Inc.$1.3M0.42%555,555Hold
23MRSNMersana Therapeutics, Inc.$1.1M0.38%904,268Hold
24PYXSPyxis Oncology, Inc (formerly Apexigen)$650,3520.22%326,810New
25WGSGeneDx Holdings Corp.$377,1180.13%103,604New

Source: SEC Form 13F filings · as of 2023-09-30